The Restless Legs Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Restless Legs Syndrome. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Restless Legs Syndrome by nine companies/universities/institutes. The top development phase for Restless Legs Syndrome is preclinical with three drugs in that stage. The Restless Legs Syndrome pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Restless Legs Syndrome pipeline products market are: Vifor Pharma Management, Relmada Therapeutics and Bioprojet SCR.

The key targets in the Restless Legs Syndrome pipeline products market include D1A Dopamine Receptor (Dopamine D1 Receptor or DRD1), D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3), and D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2).

The key mechanisms of action in the Restless Legs Syndrome pipeline product include D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3) Agonist with two drugs in Phase II. The Restless Legs Syndrome pipeline products include five routes of administration with the top ROA being Oral and one key molecule types in the Restless Legs Syndrome pipeline products market including Small Molecule.

Restless Legs Syndrome overview

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling, and cramping in the calf or leg muscles. A predisposing factor is age. Treatment includes muscle relaxants, sleep medications, and narcotic medications.

For a complete picture of Restless Legs Syndrome’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.